Loading...

PerCP/Cyanine5.5 anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_PerCPCy55_CD4_Antibody_101618
C57BL/6 mouse splenocytes stained with CD3e APC and CD4 (clone RM4-5) PerCP/Cyanine5.5 (left), or rat IgG2a, κ PerCP/Cyanine5.5 isotype (right).
  • RM4-5_PerCPCy55_CD4_Antibody_101618
    C57BL/6 mouse splenocytes stained with CD3e APC and CD4 (clone RM4-5) PerCP/Cyanine5.5 (left), or rat IgG2a, κ PerCP/Cyanine5.5 isotype (right).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
100539 25 µg $103
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100540 100 µg $283
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  2. Lee SA, et al. 2020. J Immunol. 204:586. PubMed
  3. Tian WJ, et al. 2021. Clin Exp Pharmacol Physiol. 48:902. PubMed
  4. Pohlmeier L, et al. 2021. Allergy. 76:2030. PubMed
  5. van Dierendonck XAMH, et al. 2022. Proc Natl Acad Sci U S A. 119:e2114739119. PubMed
  6. Martin-Martin I, et al. 2022. Cell Rep. 39:110648. PubMed
  7. Serra M, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:609. PubMed
  8. Chen Q, et al. 2022. Cell Rep. 39:110990. PubMed
  9. Balood M, et al. 2022. Nature. 611:405. PubMed
  10. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  11. Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed
  12. Hajnik RL, et al. 2022. Sci Transl Med. 14:eabq1945. PubMed
  13. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  14. Hao H, et al. 2023. Nat Biomed Eng. . PubMed
  15. Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed
  16. Liu KY, et al. 2023. Environ Health Perspect. 131:37014. PubMed
  17. Zeng S, et al. 2023. Front Oncol. 13:1171926. PubMed
  18. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  19. Kim TJ, et al. 2019. Nat Commun. 10:3258. PubMed
  20. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  21. Baldwin SL, et al. 2021. PLoS One. 16:e0247990. PubMed
  22. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  23. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  24. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  25. Tyagi AM et al. 2018. Immunity. 49(6):1116-1131 . PubMed
  26. Böttcher JP, et al. 2018. Cell. 172:1022. PubMed
  27. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  28. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  29. Castiglioni A, et al. 2015. PLoS One. 10:128094. PubMed
  30. Isakova-Sivak I, et al. 2020. Vaccines (Basel). 8:00. PubMed
  31. Yu M, et al. 2021. J Clin Invest. 131:. PubMed
  32. Kitano M, et al. 2016. Proc Natl Acad Sci U S A. 113: 1044 - 1049. PubMed
  33. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  34. Solanki A, et al. 2018. Development. 145. PubMed
  35. Willingham SB, et al. 2018. Cancer Immunol Res. 6:1136. PubMed
  36. Voisin M, et al. 2021. Commun Biol. 4:420. PubMed
  37. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  38. JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed
  39. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  40. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  41. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  42. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  43. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  44. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  45. Tyagi AM, et al. 2021. eLife. 10:00. PubMed
  46. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  47. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  48. Vogel AB, et al. 2021. Nature. 592:283. PubMed
  49. Gniadek TJ, et al. 2020. J Immunother. 43:217. PubMed
  50. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  51. White C, et al. 2015. J Immunol. 194:697. PubMed
  52. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  53. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  54. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  55. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  56. Ishikawa E, et al. 2016. Nat Commun. 7: 12756. PubMed
  57. Lim S, et al. 2016. PLoS One. 11: 0155689. PubMed
  58. Duan H et al. 2018. Immunity. 49(2):301-311 . PubMed
  59. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  60. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  61. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  62. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  63. Lebrun A, et al. 2015. J Immunol. 195: 4358 - 4368. PubMed
  64. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  65. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  66. Nagashima H et al. 2019. Immunity. 51(4):682-695 . PubMed
  67. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  68. Chen X, et al. 2021. Immunity. 54(2):324-339.e8. PubMed
  69. Yue X, et al. 2021. EMBO Rep. 22:e52716. PubMed
  70. Lainé A, et al. 2021. Nat Commun. 12:6228. PubMed
  71. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  72. Sun X, et al. 2017. Microbes Infect. 10.1016/j.micinf.2017.08.007. PubMed
  73. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  74. Matsumoto M, et al. 2021. Cell Host Microbe. 29(6):930-940.e4. PubMed
  75. Ren S, et al. 2022. Int J Biol Sci. 18:166. PubMed
  76. Chen X, et al. 2022. STAR Protoc. 3:101180. PubMed
  77. Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed
  78. Rossnagl S, et al. 2016. PLoS Biol. 14: 1002562. PubMed
  79. Zeng J, et al. 2020. Int J Biol Sci. 1.939583333. PubMed
  80. Aalipour A, et al. 2020. Mol Ther Oncolytics. 17:232. PubMed
  81. Kunishita Y, et al. 2020. Front Immunol. 11:98. PubMed
  82. Silva HM, et al. 2019. J Exp Med. 216:786. PubMed
  83. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  84. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  85. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
RRID
AB_893326 (BioLegend Cat. No. 100539)
AB_893326 (BioLegend Cat. No. 100540)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Go To Top Version: 3    Revision Date: 01/29/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account